Search

The Huber lab is focused on understanding how activity-regulated transcription and translation in neurons controls synapse and circuit plasticity and development.

Learn how we extract more complete informational content from sequenced genomes and advance the operational definition of "genetic meaning."

Meet the incredible people who support the Dan Tong Lab.

Our research program focuses on understanding how dysregulation of lipid uptake and trafficking contributes to human diseases. 

The German Lab focuses its research on Neurodegenerative Diseases and Autism.

Skip to main content Contact us Will Prinz, Ph.D. Professor and Chair of Cell Biology department Address: 6000 Harry Hines blvd, NL06-116AA, Tx 75390, USA Email: Email Phone: 214-648-0129 Alexandre Toulmay, Ph.D. Assistant professor Address: 6000 Harry Hines blvd, NL05-120, Tx 75390, USA Email: Email…

Satterthwaite Lab studies the signals that control B lymphocyte development, activation, and differentiation into antibody-secreting plasma cells, both normally and in autoimmune diseases such as lupus. We hope that by defining these events, we can reveal new approaches to modulate antibody responses therapeutically.

The Cobb lab studies signal transduction mechanisms of protein kinases and how kinase structures lead to cell biological functions. We are particularly focused on the contributions of ERK MAP kinases to pancreatic beta-cell function and to lung cancers, and on the cell biological actions of WNK protein kinases.

The Terada Lab is focused on several areas of cellular signaling which control basic mechanical and cell fate decision programs. 

The discovery of ANP many years ago sparked interest in the use of natriuretic peptides to diagnose and treat heart failure and other salt-retaining disorders. Since then, there have been successes and failures. A more comprehensive understanding of the natriuretic peptide system, including the role of noncardiac factors such as race/ethnicity, may encourage more targeted approaches. One of the original insights of de Bold et al, was that the heart is an endocrine organ. Endocrine therapies are administered to individuals with specific evidence of endocrine dysfunction, not to capture short-term beneficial effects. For instance, thyroid hormone is given only to patients in whom hypothyroidism is demonstrated, not based on its metabolic actions. Studies are warranted to determine whether a similar strategy for the heart’s endocrine system can advance the prevention and treatment of cardiometabolic disease. CMRU is strategically positioned to advance research toward this important strategic goal.